EGFR tyrosine kinase domain mutations in human gliomas
作者： Y Marie , AF Carpentier , AMP Omuro , M Sanson , J Thillet
DOI: 10.1212/01.WNL.0000158654.07080.B0
关键词:
摘要: Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor effective in patients with lung cancer mutations exons 19 and 21 of the EGFR domain. In this study, authors tested presence such 95 gliomas including glioblastomas, anaplastic oligodendrogliomas, low-grade gliomas. No mutation was found, which suggests that biology different from may be a resistance glioblastomas to gefitinib.
sci-hub.se 参考文章(7)
W Gillies McKenna, Hui-Kuo G Shu, Bin Li, Chi-Ming Chang, Min Yuan, Resistance to Small Molecule Inhibitors of Epidermal Growth Factor Receptor in Malignant Gliomas Cancer Research. ,vol. 63, pp. 7443- 7450 ,(2003)
Narendra Nathoo, Samuel Goldlust, Michael A. Vogelbaum, Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas. Neurosurgery. ,vol. 54, pp. 1480- 1489 ,(2004) , 10.1227/01.NEU.0000125006.88478.F6
Mark R. Green, Targeting Targeted Therapy The New England Journal of Medicine. ,vol. 350, pp. 2191- 2193 ,(2004) , 10.1056/NEJME048101
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, H. Varmus, EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Proceedings of the National Academy of Sciences of the United States of America. ,vol. 101, pp. 13306- 13311 ,(2004) , 10.1073/PNAS.0405220101
J Guillermo Paez, Pasi A Janne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon, Katsuhiko Naoki, Hidefumi Sasaki, Yoshitaka Fujii, Michael J Eck, William R Sellers, Bruce E Johnson, Matthew Meyerson, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. ,vol. 304, pp. 1497- 1500 ,(2004) , 10.1126/SCIENCE.1099314
EGFR mutations and sensitivity to gefitinib. The New England Journal of Medicine. ,vol. 351, pp. 1260- 1261 ,(2004) , 10.1056/NEJM200409163511221